Genzyme/Ilex merger
Executive Summary
Federal Trade Commission issues second request for information on Genzyme/Ilex merger. FTC is investigating whether Ilex' leukemia agent Campath, which is being studied by independent researchers as a transplant treatment, would overlap with Genzyme's renal transplant agent Thymoglobulin. Companies announced Genzyme's $1 bil. acquisition of Ilex on Feb. 26 (1"The Pink Sheet" March 1, 2004, p. 12)...